Somituximab (Mirvetuximab) single dosage specification

The dosage of somituximab(Mirvetuximab) for the treatment of ovarian cancer is strictly based on body weight and clinical guidelines to ensure drug efficacy and safety. The recommended dose for ELAHERE trials and clinical use is 6 mg/kg, calculated based on ideal body weight, administered via intravenous infusion once every 3 weeks (21-day cycle). The dosing cycle continues until disease progression or intolerable toxicity occurs. This dosage design fully takes into account the drug's pharmacokinetic properties and tumor cell killing mechanism, ensuring both effective treatment and patient tolerance.

Before infusion, patients need to receive systemic conditioning to reduce the risk of drug-related infusion reactions. Routine pretreatment including corticosteroids, antihistamines, and antipyretic medications can be effective in reducing allergic or infusion reactions. In addition, to prevent ocular adverse reactions and improve tolerance, doctors may recommend the use of antiemetics, ocular steroid ointments, and lubricating eye drops. Pretreatment measures are a key link to ensure the safety of a single dose, reduce side effects, and improve patient compliance.

Somituximabas an antibody-drug conjugate, binds to the FRα receptor of tumor cells and delivers cytotoxic drugs directly to the interior of cancer cells to achieve precise killing. A single dose of 6 mg/kg is designed to maintain a sufficient effective concentration in the blood and tissues, continue to act on cancer cells, and reduce damage to normal tissues. Clinical studies have shown that standardized dose infusion can significantly improve patients' tumor burden, serum tumor marker levels and quality of life, while reducing the incidence of serious adverse events.

In short, the single dose specification of somituximab is6 mg/kg, calculated based on ideal body weight, through intravenous infusion, once every 3 weeks, and with adequate pretreatment measures, it can ensure the efficacy while reducing the risks associated with infusion, and it is currently the standard medication regimen recommended in international clinical settings.

Reference materials:https://www.elahere.com/